191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. (December 2022) - Jimeno, A.; Miselis, N.R.; Park, J.C.; Jennings, J.; Dhani, N.; Holtick, U.; Iams, W.T.; Rodabaugh, K.; Nair, N.; Kornacker, M.; Loughhead, S.M.; Bernstein, H.; et al.